Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jan 4;151(1):214-222.
doi: 10.1093/jn/nxaa353.

Fewer Community-Acquired Colds with Daily Consumption of Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2. A Randomized, Placebo-Controlled Clinical Trial

Irini Lazou Ahrén  1 , Magnus Hillman  2 , Elisabet Arvidsson Nordström  1 , Niklas Larsson  1 , Titti Martinsson Niskanen  1
Affiliations
Randomized Controlled Trial

Fewer Community-Acquired Colds with Daily Consumption of Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2. A Randomized, Placebo-Controlled Clinical Trial

Irini Lazou Ahrén et al. J Nutr. .

Abstract

Background: Viral infections of the upper airways are the most common cause for absence from work or school, and there is evidence for probiotic efficacy in reducing the incidence and severity of these infections.

Objectives: We aimed to confirm the previously reported beneficial effects of Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2 against community-acquired common colds and identify a possible mechanism of action.

Methods: In a double-blind study, healthy adults (18-70 years of age) with at least 4 colds during the last 12 months before recruitment were randomly allocated to consume either probiotics (n = 448; total daily dose of 109 CFU with the 2 strains equally represented) or placebo (n = 450) once daily for 12 weeks. Recruitment took place from October to February during 2013-2016 (over 3 cold seasons). The probiotic impact on the severity of the colds (Wisconsin Upper Respiratory Symptom Survey-21) was the primary endpoint, whereas secondary endpoints included the incidence rate and duration of colds and an analysis of immune markers. Mann-Whitney U test and mixed model were used for the analysis of continuous variables and Fisher´s exact test was used for the analysis of categorical endpoints.

Results: Symptom severity was not reduced after intake of the probiotic, despite the positive trend seen in the first season. However, significantly fewer colds were experienced in the probiotic group (mean of 1.24 colds) as compared to the placebo group (mean of 1.36 colds; P = 0.044) for subjects reporting at least 1 cold, the incidence of recurring colds was 30% lower (20.8% vs. 29.8%, respectively; P = 0.055), and the use of analgesics was 18% lower (26.3% vs. 32%, respectively; P = 0.07). After 12 weeks, the change from baseline for IFN-γ differed between the groups (mean difference of -7.01; 95% CI, -14.9 to 0.93; P = 0.045).

Conclusions: Intake of Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2 can be protective against multiple colds in adults prone to getting colds.This trial was registered at clinicaltrials.gov as NCT02013934.

Keywords: Lacticaseibacillus paracasei; Lactiplantibacillus plantarum; Probi Defendum®; probiotic; respiratory tract infections.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Participant flowchart. Abbreviation: ITT, intent to treat.
FIGURE 2
FIGURE 2
Mean daily WURSS-21 symptom score in the analysis, including all subjects randomized in the study and in each of the 3 seasons separately. Subjects without valid colds contribute with a severity score equal to “0.” Data represent means ± SDs. A Mann-Whitney U test was performed to detect differences between the 2 groups. Probiotic group: 2013–2014, n = 123; 2014–2015, n = 255; and 2015–2016, n = 70. Placebo group: 2013–2014, n = 126; 2014–2015, n = 254; and 2015–2016, n = 70. *P < 0.05. Abbreviation: WURSS-21, Wisconsin Upper Respiratory Symptom Survey−21.
See this image and copyright information in PMC

References

    1. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–14. - PubMed
    1. Maldonado Galdeano C, Cazorla SI, Lemme Dumit JM, Vélez E, Perdigón G. Beneficial effects of probiotic consumption on the immune system. Ann Nutr Metab. 2019;74(2):115–24. - PubMed
    1. La Fata G, Weber P, Mohajeri MH. Probiotics and the gut immune system: indirect regulation. Probiotics Antimicrob Proteins. 2018;10(1):11–21. - PMC - PubMed
    1. Liu Y, Tran DQ, Rhoads JM. Probiotics in disease prevention and treatment. J Clin Pharmacol. 2018;58(Suppl 10):S164–79. - PMC - PubMed
    1. Håkansson Å, Andrén Aronsson C, Brundin C, Oscarsson E, Molin G, Agardh D. Effects of Lactobacillus plantarum and Lactobacillus paracasei on the peripheral immune response in children with celiac disease autoimmunity: a randomized, double-blind, placebo-controlled clinical trial. Nutrients. 2019;11:E192531426299. - PMC - PubMed

Publication types

Associated data